Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6)

详细信息    查看全文

• 作者：Jolie Ringash^a ; ^{jolie.ringash@rmp.uhn.on.ca} ; John N. Waldron^a ; Lillian L. Siu^a ; Rosemary Martino^b ; Eric Winquist^c ; Jim R. Wright^d ; Abdenour Nabid^e ; John H. Hay^f ; Alex Hammond^c ; Khalil Sultanem^g ; Sebastien Hotte^d ; Carson Leong^h ; Ali Abdel Halim El-Gayedⁱ ; Farah Naz^j ; Kevin Ramchandar^k ; Timothy E. Owen^l ; Alexander Montenegro^m ; Brian O'Sullivan^a ; Bingshu E. Chen^m ; Wendy R. Parulekar^m
• 关键词：Randomised clinical trial ; Phase III clinical trial ; Head and neck neoplasms ; Intensity-modulated radiation therapy ; Cisplatin ; Concurrent chemoradiotherapy ; Quality of life ; Swallowing ; Patient-reported outcomes
• 刊名：European Journal of Cancer
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：72
• 期：Complete
• 页码：192-199
• 全文大小：961 K
• 卷排序：72

文摘

Three hundred twenty head and neck cancer patients participated in a phase III randomised trial comparing standard radiotherapy /cisplatin with accelerated radiotherapy/panitumumab. Quality of life (QOL) and swallowing outcomes were compared between arms. No clinically important differences by arm were seen 2–36 months post-treatment. Swallowing and head and neck–specific QOL showed persistent declines in both study arms. These results do not suggest adopting the experimental arm to improve QOL.